两种西药联合治疗轻度脑小血管病性认知功能损害的疗效

Therapeutic effects of two western medicines combined in the treatment of mild cognitive impairment with cerebral small vessel disease

目的研究联合应用阿托伐他汀和尼莫地平治疗轻度脑小血管病(CSVD)性认知功能损害的效果。方法将我院2017年1月至2017年7月收治的轻度CSVD性认知功能损害患者90例随机分为单一组(40例,用尼莫地平治疗)与联合组(50例,联合阿托伐他汀与尼莫地平治疗)。治疗半年后,比较两组临床疗效及神经功能改善情况。结果治疗后,两组患者的NIHSS评分均降低,MoCA评分均升高,且联合组NIHSS与MoCA评分均优于单一组(P<0.05)。治疗后,联合组TC、TG、LDL-C水平低于单一组与治疗前(P<0.05)。结论阿托伐他汀联合尼莫地平治疗轻度CSVD性认知功能损害能够更明显改善临床症状,提升患者神经功能,同时改善患者血脂水平,可在临床广泛推广。

Objective To study the effect of atorvastatin and nimodipine combined in the treat ment of mild cognitive impairment of cerebral small vessel disease（CSVD）.Methods A total of 90 patients with mild cognitive impairment of CSVD admitted in our hospital from January 2017 to July 2017 were randomly divided into single group（n =40, given nimodipine treatment） and combination group（n=50, given atorvastatin and nimodipine treatment） according to the different medications methods. After treatment for half a year, the clinical efficacy and neurologic function improvement of the two groups were compared.Results After treatment, the NIHSS scores decreased and MoCA scores increased in the two groups,and the NIHSS and MoCA scores of the combination group were better than those of the single group（P〈0.05）. After treatment, the levels of TC, TG, and LDL-C of the combination group were significantly lower than those of the single group and before treatment（P〈0.05）.Conclusion Atorvastatin combined with nimodipine in the treatment of mild cognitive impairment of CSVD can significantly improve the clinical symptoms, improve the neurological function and the blood lipid levels of patients, which can be widely used in clinic.